The names at the forefront of weight loss drugs are Eli Lilly, the U.S. manufacturer of Mounjaro and Zepbound; and Novo ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Weight-loss surgery can protect the liver health of patients with obesity and fatty liver disease, a new study repor ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Imagine being one of the millions of Americans in need of a hip or knee replacement due to osteoarthritis. Severe pain, reduced physical activity, an inability to perform many routine tasks — the ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.